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Reactive oxygen species (ROS) at physiological levels are important cell signaling
molecules. However, aberrantly high ROS are intimately associated with disease and com-
monly observed in cancer. Mitochondria are primary sources of intracellular ROS, and their
maintenance is essential to cellular health. Autophagy, an evolutionarily conserved process
whereby cytoplasmic components are delivered to lysosomes for degradation, is responsi-
ble formitochondrial turnover and removal of damagedmitochondria. Impaired autophagy is
implicated in many pathological conditions, including neurological disorders, inﬂammatory
bowel disease, diabetes, aging, and cancer. The ﬁrst reports connecting autophagy to can-
cer showed that allelic loss of the essential autophagy gene BECLIN1 (BECN1) is prevalent
in human breast, ovarian, and prostate cancers and that Becn1+/− mice developmammary
gland hyperplasias, lymphomas, lung and liver tumors. Subsequent studies demonstrated
that Atg5−/− and Atg7−/− livers give rise to adenomas, Atg4C−/− mice are susceptible to
chemical carcinogenesis, and Bif1−/− mice are prone to spontaneous tumors, indicating
that autophagy defects promote tumorigenesis. Due to defective mitophagy, autophagy-
deﬁcient cells accumulate damaged mitochondria and deregulated ROS levels, which likely
contribute to their tumor-initiating capacity. However, the role of autophagy in tumorige-
nesis is complex, as more recent work also revealed tumor dependence on autophagy:
autophagy-competent mutant-Ras-expressing cells form tumors more efﬁciently than their
autophagy-deﬁcient counterparts; similarly, FIP200 deﬁciency suppresses PyMT-driven
mammary tumorigenesis.These latter ﬁndings are attributed to the fact that tumors driven
by powerful oncogenes have high metabolic demands catered to by autophagy. In this
review, we discuss the relationship between ROS and autophagy and summarize our
current knowledge on their functional interactions in tumorigenesis.
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INTRODUCTION
Reactive oxygen species (ROS) are a family of molecules that
include highly reactive free oxygen radicals, such as the super-
oxide anion (O·−2 ) and the hydroxyl radical (OH·), and stable
non-radical oxidants, such as hydrogen peroxide (H2O2). ROS
are produced in cells through metabolism of oxygen and, when
at high levels, can function as destructive molecules, actively par-
ticipating in microbial elimination within phagocytes and also
contributing to genomic instability, thereby resulting in cell death
and/or tumorigenesis. In more recent years, however, ROS at
Abbreviations:AMBRA, activatingmolecule in beclin 1-regulated autophagy; AMP,
adenosinemonophosphate; AMPK,AMPactivated protein kinase; ARE, antioxidant
response element; ASC, apoptosis-associated speck-like protein containing a CARD;
Atg 3, autophagy-related 3; Atg4C, autophagy-related 4C;Atg5, autophagy-related 5;
Atg7, autophagy-related 7; Atg8/LC3, autophagy-related 8/microtubule-associated
protein light chain 3; Atg10, autophagy-related 10; Atg12, autophagy-related
12; mAtg13, mammalian autophagy-related 13; Atg16L, autophagy-related 16-
like; ATM, ataxia-telangiectasia mutated; ATP, adenosine triphosphate; Bcl-2, B
cell CLL/lymphoma 2; Beclin1, coiled-coil myosin-like BCL2-interacting pro-
tein; BHA, butylated hydroxyanisole; Bif1, Bax interacting factor 1; BNIP3,
BCL2/adenovirus E1B 19 kDa interacting protein 3; BNIP3L/Nix, BCL2/adenovirus
E1B interacting protein 3-like/NIP3-like protein X; CCCP, carbonyl cyanide
lower physiological levels have been recognized as intracellular sig-
nal transduction molecules that regulate kinase-driven pathways,
in turn mediating cellular responses to external stimuli or chal-
lenges, such as growth factors, nutrient deprivation, or hypoxia
(Gough and Cotter, 2011). Mitochondria are a major source of
intracellular ROS, as leaky electrons from oxidative phosphory-
lation [1–5% of electrons escape from complexes I and III along
the electron transport chain (ETC)] and enzymatic complexes,
such as α-glycerophosphate dehydrogenase and α-ketoglutarate
dehydrogenase, generate short-lived superoxide anions in the
m-chlorophenylhydrazone; Deptor, DEP domain containing MTOR-interacting
protein; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; EGF,
epidermal growth factor; ER, endoplasmic reticulum; ERK1/2, extracellular reg-
ulated kinase 1/2; Ero1, endoplasmic reticulum oxidoreductin-1; ETC, electron
transport chain; FGFR-1, ﬁbroblast growth factor receptor-1; FIP200, FAK family
kinase-interacting protein of 200 kDa; FOXO1/O3, forkhead box protein O1/O3;
GAP,GTPase activatingprotein;HIF-1α, hypoxia-inducible factor-1 alpha;HMGB1,
high mobility group box 1; H2O2, hydrogen peroxide; iBMKs, immortalized baby
mouse kidney cells; IL-1β, interleukin 1 beta; IL-18, interleukin 18; IL-1R, inter-
leukin 1 receptor; iMMECs, immortalized mouse mammary epithelial cells; JNK,
c-Jun N-terminal kinase 1; Keap1, Kelch-like ECH-associated protein 1; LKB1,
liver kinase B1; MAPK, mitogen-activated protein kinase; MEFs, mouse embryonic
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presence of oxygen, which are rapidly converted into relatively
stable and membrane diffusible hydrogen peroxide by superox-
ide dismutase (Mn-SOD), a resident protein of the mitochondrial
matrix (Karihtala and Soini, 2007;Miao and St Clair, 2009;Marchi
et al., 2012). Other important intracellular sources of ROS include
enzymes, such as the nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidases, xanthine oxidase (XO), the ER luminal
thiol oxidase Ero1, and myeloperoxidase (Arnhold and Flemmig,
2010; Tavender and Bulleid, 2010; Dikalov, 2011; Fransen et al.,
2012), as well as other organelles, such as peroxisomes (Fransen
et al., 2012). Reactive nitrogen species (RNS), such as nitric oxide
(NO) and peroxynitrite (ONOO), also act as signaling agents
regulating numerous physiological and pathological conditions
(Fukuto et al., 2012; Lee et al., 2012); however, in this review we
will only focus on ROS.
At physiological levels, ROS function as signaling molecules
through oxidation of redox-sensitive cysteine residues and resul-
tant inhibition of phosphatases that negatively regulate signaling
cascades (Meng et al., 2002), whereas excessive ROS create an
imbalance between the oxidant and antioxidant responses in cells,
thus resulting in oxidative stress, which has been etiologically
implicated in the pathogenesis of several malignancies, includ-
ing breast, lung, liver, and prostate cancers (Moller et al., 2008;
Nowsheen et al., 2009; Khandrika et al., 2009; Severi et al., 2010;
Adcock et al., 2011; Sakaguchi et al., 2011; Vera-Ramirez et al.,
2011; Thapa and Ghosh, 2012). Abnormally high ROS levels
result in oxidation of nuclear and mitochondrial DNA, pro-
teins and lipids, thus impairing their structure and function and
causing aberrant expression and regulation of tumor-promoting
proteins and/or pathways (Valko et al., 2006). Indeed, high lev-
els of malondialdehyde, a marker of lipid peroxidation, are
observed in plasma samples from patients with breast cancer
as compared to normal controls (Huang et al., 1999; Gonenc
et al., 2001; Kumaraguruparan et al., 2002; Polat et al., 2002;
Yeh et al., 2005; Sener et al., 2007). Conversely, overexpression
of the antioxidant enzymes copper/zinc superoxide dismutase
ﬁbroblasts; MFN1/2, mitofuscin 1/2; mLST8, MTOR-associated protein, LST8
homolog; MMTV,mouse mammary tumor virus; Mn-SOD,manganese superoxide
dismutase; mTORC1, mammalian target of rapamycin 1; NAC, N-acetyl cysteine;
NADPH oxidase, nicotinamide adenine dinucleotide phosphate-oxidase; NF-κB,
nuclear factor kappa B; NLR, Nod-like receptor; NLRP3, NLR family, pyrin domain
containing 3; NO, nitric oxide; Nrf2, nuclear factor erythroid 2-related factor 2;
O·−2 , superoxide anion; OH·, hydroxyl radical; ONOO, peroxynitrite; p62/SQSTM1,
sequestosome 1; p150, phosphatidylinositol 3-kinase-associated p150; PAO, pheny-
larsine oxide; Parkin, Parkinson protein, E3 ubiquitin protein ligase; PDGF,
platelet-derived growth factor; PDK1, phosphoinositide-dependent kinase 1; PE,
phosphatidyl ethanolamine; PERK, PRKR-like endoplasmic reticulum kinase; PH,
Pleckstrin homology; PI3K/Vps34, phosphatidylinositol 3-kinase/vacuolar protein
sorting 34; PINK1, PTEN-induced putative kinase 1; PIP2, phosphatidylinositol-
4,5-phosphate; PIP3, phosphatidylinositol-3,4,5-phosphate; PKB/Akt, protein
kinase B-alpha; PRAS40, proline-rich AKT substrate, 40 kDa; Prdx1/2, peroxire-
doxin 1/2; PTEN, phosphatase and tensin homolog; PyMT, polyoma middle T;
Rag, Ras-related GTP-binding protein; RAGE, receptor for advanced glycation end
products; Raptor, regulatory associated protein of MTOR, complex 1; Rheb, Ras
homolog enriched in brain; RNS, reactive nitrogen species; ROS, reactive oxygen
species; RUBICON,RUNdomainBeclin 1-interacting cysteine-rich-containingpro-
tein; Sesns, sestrins; SOD1, copper/zinc superoxide dismutase; SOD2, manganese
superoxide dismutase; TLRs, Toll-like receptors; TSC 1/2, tuberous sclerosis 1/2;
UBA, ubiquitin-associated; ULK1/2, Unc-51-like kinase 1/2; UVRAG, ultraviolet
irradiation resistant-associated gene; XO, xanthine oxidase.
(SOD1) and manganese superoxide dismutase (SOD2) in human
breast cancer cell lines suppresses xenograft tumor growth (Wey-
dert et al., 2006), and transgenic overexpression of catalase
in PyMT mice diminishes tumor invasiveness and metastasis
(Goh et al., 2011).
Autophagy, derived from the Greek words for self (auto) and
eating (phagy), is an evolutionarily conserved catabolic process
that targets proteins, cytoplasm and organelles to lysosomes for
degradation, followed by recycling of free amino acids and ATP
into the cytoplasm for biomolecule synthesis within the same cell
(He andKlionsky, 2009;Yang andKlionsky, 2010). Threemodes of
autophagy exist, namely macroautophagy, microautophagy, and
chaperone-mediated autophagy. Microautophagy and chaperone-
mediated autophagy are characterized by the direct delivery of
cargo into lysosomes, while macroautophagy (hereafter referred
to as autophagy) is marked by the formation of double mem-
brane vesicles, which capture cytoplasmic material for delivery to
lysosomes. While autophagy occurs at a basal level in most tis-
sue types and promotes cellular homeostasis by recycling proteins
and organelles, it is up-regulated in response to cellular insults,
such as glucose and amino acid deprivation, hypoxia, oxidative
stress, and chemotherapeutic drugs. Impaired autophagy has been
implicated in the pathogenesis of diverse diseases, including can-
cer, diabetes, Crohn’s disease, and neurodegenerative conditions,
like Alzheimer’s, Parkinson’s, and Huntington’s disease (Sridhar
et al., 2012; Quan et al., 2012).
The role of autophagy in tumorigenesis is complex. Allelic
loss of the essential autophagy regulator BECLIN1 (BECN1) is
observed in over 50% of human breast, ovarian, and prostate
cancers (Aita et al., 1999), and Becn1+/− mice are susceptible to
hepatocellular carcinomas, lung adenocarcinomas, lymphomas,
andmammary glandhyperplasias (Qu et al., 2003;Yue et al., 2003).
Furthermore, autophagy-compromised, apoptosis-defective
immortalized mouse mammary epithelial cells (iMMECs) and
babymouse kidney (iBMK) cells generate allograft tumors in nude
micemore efﬁciently than their wild-type counterparts (Karantza-
Wadsworth et al., 2007; Mathew et al., 2007). Mice lacking Bif1, a
positive regulator of autophagy, are prone to spontaneous lym-
phomas, sarcomas, duodenal adenocarcinomas, small cell lung
carcinomas, esophageal squamous cell carcinomas, and hepato-
cellular carcinomas (Takahashi et al., 2007), whereas Atg4C−/−
mice are susceptible to chemical-induced ﬁbrosarcomas (Marino
et al., 2007), and Atg5 or Atg7 deletion in the liver results in hep-
atocellular adenomas (Takamura et al., 2011; Inami et al., 2011).
Paradoxically though, autophagy is required for the robust pro-
gression of tumors (Guo et al., 2011; Lock et al., 2011; Kim et al.,
2011; Yang et al., 2011) and also supports PyMT-driven mam-
mary tumorigenesis, as loss of FIP200, a positive regulator of
autophagy, inhibits primary tumor formation andmetastasis (Wei
et al., 2011). This conundrum can be, at least partially, attributed
to the important roles of autophagy in both maintenance of cellu-
lar homeostasis under regular growth conditions and protection of
cell viability under stress. As a housekeeping pathway, autophagy
degrades damaged or aggregated proteins and organelles, which
are known sources of ROS, thereby preventing tumor initiation
via suppression of oxidative and genotoxic stress (Karantza-
Wadsworth et al., 2007; Mathew et al., 2007). On the other hand,
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oncogene activation increases the metabolic demands of trans-
formed cells and intact autophagy supports tumor cell survival
by providing substrates for mitochondrial metabolism (Guo et al.,
2011). How the functional status of autophagy impacts tumorige-
nesis is still under investigation, and tissue- and context-speciﬁc
roles are likely to be revealed.
This review will focus on the interplay between ROS and
autophagy and their functional interactions in the context of
cancer.
AUTOPHAGIC MACHINERY
Early work led to the identiﬁcation of several Atg (Autophagy-
related) genes, which are indispensable for the functional exe-
cution of the autophagic cascade in yeast. Most yeast Atg
proteins have mammalian homologs participating in a simi-
larly ordered process. Initiation of autophagy is characterized
by the formation of nascent double membrane structures called
phagophores, which elongate and enclose cytoplasmic material
in vesicles or autophagosomes. Mature autophagosomes sub-
sequently fuse with lysosomes to form autolysosomes, thereby
leading to the degradation of cargo and the release of amino acids
and ATP into the cytoplasm (He and Klionsky, 2009; Yang and
Klionsky, 2010).
In mammalian cells, under nutrient-rich conditions, the
nutrient sensor and serine/threonine kinase mammalian target
of rapamycin complex 1 (mTORC1) phosphorylates ULK1/2,
and mAtg13, preventing the assembly of a multi-protein com-
plex, which is required for autophagosome formation. Under
starvation, mTORC1 is inactivated, ULK1/2 undergo autophos-
phorylation, and then phosphorylate mAtg13 and FIP200 to form
an ULK1/2–mAtg13–FIP200 complex that is stabilized by Atg10
(Hara et al., 2008; Ganley et al., 2009; Hosokawa et al., 2009; Jung
et al., 2009; Mercer et al., 2009). The nucleation and formation
of the phagophore also requires the Class III PI3K/Vps34 com-
plex, which consists of PI3K/Vps34, the serine/threonine kinase
p150 and Beclin1; this complex is positively regulated by Atg14L,
the ultraviolet irradiation resistant-associated gene (UVRAG), the
Bax-interacting factor 1 (Bif-1), and the activating molecule in
Beclin 1-regulated autophagy (AMBRA), and negatively regulated
by the RUN domain Beclin 1-interacting cysteine-rich-containing
protein (RUBICON; Kihara et al., 2001; Liang et al., 2006; Fimia
et al., 2007; Takahashi et al., 2007; Sun et al., 2008; reviewed in
Yang and Klionsky, 2010). The ULK and the Class III PI3K
complexes recruit two ubiquitin-like conjugation systems for
expansion of the autophagosome membrane. Following activa-
tion by Atg7 (E1-like enzyme), Atg12 is transferred to Atg10
(E2-like enzyme) and becomes covalently bound to Atg5 via a
lysine residue. Atg16L combines with Atg5–Atg12 to form the
Atg5–Atg12–Atg16L complex that self-oligomerizes and binds to
the phagophore (Mizushima et al., 1998, 2001, 2003; Tanida et al.,
2001; reviewed in He and Klionsky, 2009). Similarly, following
cleavage at its C-terminus by the cysteine protease Atg4 and acti-
vation by Atg7 (E1-like enzyme), Atg8 (or LC3) is transferred to
Atg3 (E2-like enzyme), conjugated to phosphatidylethanolamine
(PE) and incorporated into the autophagosome membrane, in
a process facilitated by – but not exclusively dependent on –
the Atg5–Atg12 complex (Kabeya et al., 2000; Tanida et al., 2002;
Nishida et al., 2009; reviewed in He and Klionsky, 2009). Atg4
can also delipidate LC3-PE to release LC3 from autophagosomes
and, thus, increase the free LC3 pool (Kabeya et al., 2004; Tanida
et al., 2004). The protein p62/SQSTM1, which accumulates under
conditions of oxidative stress, binds to ubiquitinated proteins via
its ubiquitin-associated (UBA) domain, sequesters them by self-
oligomerization, and delivers them to autophagosomes via its LC3
binding domain (Bjorkoy et al., 2005; Komatsu et al., 2007; Pankiv
et al., 2007). Finally, the autophagosomal cargo, including p62, is
degraded in lysosomes (Bjorkoy et al., 2005; Komatsu et al., 2007;
Pankiv et al., 2007).
CROSSTALK BETWEEN ROS AND AUTOPHAGY: ROS
MODULATE AUTOPHAGY
AUTOPHAGY INDUCTION IN RESPONSE TO ROS
Direct effect on Atg proteins
Amino acid deprivation induces the formation of H2O2 in mito-
chondria in a Class III PI3K-dependent manner, and this ROS
is essential for the induction of autophagy in response to starva-
tion (Scherz-Shouval et al., 2007). Speciﬁcally, the Cys81 residue
near the catalytic site of Atg4 is a direct oxidation target by
H2O2; its oxidized form inactivates the protease activity of Atg4
and prevents the delipidation of LC3 without affecting the C-
terminal processing of LC3 by Atg4, thus leading to increased
autophagosome formation. In a reducing environment, the Atg4
protease remains active and delipidates LC3, thereby suppressing
autophagosome membrane formation and resulting in autophagy
inhibition.
Indirect induction of autophagy
The energy-dependent activity of mTOR is regulated by the
heterotrimeric enzyme AMPK,which is in turn activated by phos-
phorylation in response to high intracellular AMP/ATP ratios.
Under nutrient-depleted conditions, active AMPK phosphory-
lates TSC2, as well as the mTORC1 subunit Raptor, effectively
preventing the activation of mTORC1 and, therefore, inducing
autophagy (Inoki et al., 2003; Gwinn et al., 2008). More recent
studies demonstrate a direct role for AMPK in the induction of
autophagy. Under glucose deprivation, AMPK directly activates
ULK1 by phosphorylation at Ser317 and Ser777 and results in the
induction of autophagy (Kim et al., 2011). In another study, phos-
phorylated ULK1 (at Ser555) is detected in wild-type hepatocytes,
but not in hepatocytes from AMPK−/− mice treated with met-
formin, an activator of AMPK (Egan et al., 2011). Reconstitution
of ULK1 in ULK1−/− MEFs, but not a mutated ULK1 construct
lacking the AMPK phosphorylation site, rescues the viability of
cells under starvation by the induction of mitochondrial-speciﬁc
autophagy (Egan et al., 2011). AMPK is a major mediator of
indirect activation of autophagy by ROS, as it is sensitive to
oxidative stress induced by H2O2 and gets phosphorylated at
Thr172 of its α1 catalytic subunit (Choi et al., 2001). AMPK
also induces autophagy in Atg5- and LKB1-, but not AMP/ATP
ratio-, dependent manners in response to hypoxia-associated
mitochondrial ROS production (Papandreou et al., 2008;
Emerling et al., 2009).
Reactive oxygen species-associated autophagy induction is also
mediated by ataxia-telangiectasia mutated (ATM), a kinase that is
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critical for orchestrating cellular responses to DNA damage and,
in parallel to its nuclear functions, increases TSC2 activity in the
cytoplasm via the LKB1/AMPK metabolic pathway, thus resulting
in mTORC1 inactivation (Alexander et al., 2010). Similarly, ROS-
induced and p53-activated sestrins (Sesns) have been shown to
suppress oxidative stress by promoting autophagy via the AMPK-
mTOR axis in Drosophila (Lee et al., 2010; Budanov, 2011)
High mobility group box 1 (HMGB1) is a nuclear protein
that is released extracellularly in response to cytokines, trauma,
and cell death, and can mediate inﬂammation by binding to
receptors, such as the receptor for advanced glycation end prod-
ucts (RAGE) and Toll-like receptors (TLRs; Lotze and Tracey,
2005; Sims et al., 2010). Recent studies demonstrated that loss
of HMGB1 attenuates autophagy (Tang et al., 2010a,b). Further-
more, HMGB1 translocates from the nucleus to the cytoplasm
in response to autophagy-inducing stimuli in a ROS-dependent
manner, since treatment with the antioxidant N-acetyl cysteine
(NAC) dampens, while loss of the antioxidant enzymes SOD1
and SOD2 promotes, autophagy induction and HMGB1 cyto-
plasmic translocation (Tang et al., 2010b). HMGB1, in turn,
promotes autophagy by disrupting the Beclin1–Bcl-2 interaction
and enhancing ERK1/2 activity (Tang et al., 2010b). The redox
sensitivity of HMGB1 is critical for autophagy induction, as oxi-
dation of cysteine residues at positions 23 and 45 is essential for
the ability of HMGB1 to disrupt the Beclin1–Bcl-2 interaction,
while Cysteine 106 is important for the cytoplasmic localization
of HMGB1 (Tang et al., 2010b). Similarly, the HMGB1 receptor
RAGE positively regulates autophagy and promotes survival of
pancreatic cancer cells upon treatment with hydrogen peroxide
(Kang et al., 2011a,b).
Hypoxia triggers an acute induction of ROS over a short period
of time, while prolonged hypoxia results in decreased intracellular
ROS levels as compared to normoxia (Semenza, 2011). Mitochon-
drial ROS generated in response to hypoxia prevent degradation
of the hypoxia-inducible factor-1 alpha (HIF-1α; Chandel et al.,
2000; Guzy et al., 2005). Hypoxia-induced stabilization of HIF-
1α leads to transcription of several target genes, including BNIP3
and BNIP3L, which induce autophagy in response to low oxy-
gen conditions (Bruick, 2000; Sowter et al., 2001; Zhang et al.,
2008; Bellot et al., 2009). In addition to hypoxia, BNIP3 mediates
autophagy induction in response to H2O2 and during myocar-
dial ischemia/reperfusion injury (Hamacher-Brady et al., 2007;
Byun et al., 2009). H2O2-responsive BNIP3-mediated induction
of autophagy occurs via dephosphorylation of mTOR at the
S2481 residue, resulting in its inactivation (Byun et al., 2009),
while hypoxia-driven autophagy induction relies on the abil-
ity of BNIP3 to bind to and interfere with the activity of the
GTPase Rheb, a positive regulator of mTORC1, thereby prevent-
ing TORC1 activation (Li et al., 2007). Additionally, mutating
a redox-sensitive cysteine residue at position 64 diminishes the
ability of BNIP3 to undergo homodimerization in response to
oxidative stress, such as that caused by ischemia and reperfusion
(Kubli et al., 2008), and this homodimerization is critical for the
interaction of BNIP3 with LC3 and the induction of autophagy
(Hanna et al., 2012).
Other mediators of autophagy induction in response to ROS
and oxidative stress include the forkhead transcriptional regulator
FOXO1 and FOXO3 (Sengupta et al., 2011), the p38 mitogen-
activated protein kinase (MAPK; Cheng et al., 2009; McClung
et al., 2010), the extracellular regulated kinase (ERK) and the c-
Jun N-terminal kinase (JNK; Wu et al., 2009; Wong et al., 2010),
and the endoplasmic reticulum kinase PERK (Avivar-Valderas
et al., 2011).
INHIBITORY EFFECT OF ROS ON POSITIVE REGULATORS OF
AUTOPHAGY
Direct effect on Atg proteins
Another point of direct autophagy regulation byROSmay be at the
two ubiquitin-like conjugation systems described earlier. While
direct evidence is lacking in this regard, it has been speculated
that the sulfhydryl group-containing ubiquitin-like enzymes Atg3,
Atg7, and Atg10 are redox-sensitive in a manner similar to the E1
and E2 enzymes of the ubiquitin system, which possess catalytic
cysteines and can undergo reversible oxidation and inactivation in
the presence of ROS (Filomeni et al., 2010).
Indirect effect on other positive autophagy regulators
Reactive oxygen species can alsomodulate autophagy indirectly by
affecting the activity of the master autophagy regulator mTORC1
rather than the Atg proteins themselves. mTORC1, a multi-
protein complex consisting of the conserved serine/threonine
kinase mTOR, Raptor, mLST8, PRAS40, and Deptor, is sen-
sitive to the availability of amino acids, growth factors, hor-
mones, and energy, and subsequently regulates translation, cell
growth, and autophagy (Zoncu et al., 2011). The GTPases Rheb
and Rag regulate the activity and the spatial localization of
mTORC1, respectively, in response to amino acid and growth
factor availability. Rheb is in turn regulated by the GTP activat-
ing proteins (GAP) TSC1/TSC2: upon amino acid and growth
factor stimulation, PKB/Akt inactivates TSC2 by phosphoryla-
tion, resulting in Rheb and mTORC1 activation and concomitant
suppression of autophagy (Zoncu et al., 2011). An earlier study
indicated that mTORC1 activity increases in the presence of
oxidizing agents, such as diamide or the cysteine oxidant pheny-
larsine oxide (PAO; Sarbassov and Sabatini, 2005), and more
recent work demonstrated that PAO activates mTORC1 via Rheb
(Yoshida et al., 2011). Interestingly, Tsc1−/− and Tsc2−/− MEFs
exhibit constitutively high, rapamycin-sensitive mTOR activity
regardless of redox modulation by an oxidant (PAO) or a reduc-
ing (British anti-Lewisite) agent, thus indicating that TSC1/2
maybe redox-sensitive proteins and potentially regulated by ROS
(Yoshida et al., 2011).
mTOR activation due to growth factor stimulation is mediated
by a number of signaling pathways, including the PI3K–Akt axis.
For instance, binding of insulin to its receptor recruits PI3K to
the cell membrane, where it phosphorylates phosphatidylinositol-
4,5-phosphate (PIP2) to generate phosphatidylinositol-3,4,5-
phosphate (PIP3) in a reaction that is reversibly catalyzed by
the phosphatase-and-PI3K antagonist PTEN (Hernandez-Aya and
Gonzalez-Angulo, 2011; Zoncu et al., 2011). Formation of PIP3
leads to recruitment and activation of PH-domain proteins, such
as PDK1 and PKB/Akt, leading to further downstream signaling
and mTORC1 activation. Activation of the PI3K axis in response
to growth factors, such as EGF, insulin, and PDGF, is facilitated by
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concomitant production of H2O2, which inactivates PTEN by oxi-
dizing a cysteine residue (Cys124) at its catalytic site and reversibly
cross-linking it toCys71 via a disulﬁde bond (Lee et al., 2002; Kwon
et al., 2004). Although not formally demonstrated, ROS-induced
inactivation of PTEN can result in increased mTORC1 activity via
the PI3K–Akt pathway, thus leading to suppression of autophagy.
An antioxidant buffer ameliorating growth factor-associated ROS
production, and thus preserving autophagy in the context of PI3K
axis activation, is provided by peroxiredoxins, particularly perox-
iredoxin I (Prdx1) and peroxiredoxin II (Prdx2), which modulate
PTEN oxidation (Kwon et al., 2004; Cao et al., 2009). Interest-
ingly,MMTV-v-H-Ras;Prdx1−/− mice developmammary tumors
at a higher frequency compared to MMTV-v-H-Ras;Prdx1+/+
mice, possibly in association with increased PTEN oxidation and
resultant PI3K/Akt/mTOR axis activation, as mammary epithelial
cells isolated from MMTV-v-H-Ras; Prdx1−/− mice demonstrate
higher levels of oxidized PTEN compared to their wild-type coun-
terparts (Cao et al., 2009). These studies indicate that ROS may
negatively regulate autophagy by mTORC1 induction via oxi-
dation and inactivation of PTEN and TSC1/2, and suggest that
other mechanism(s) protective against mTORC1 activation must
be simultaneously active, so that autophagy is allowed to proceed
as a prosurvival cell function under oxidative stress.
CROSSTALK BETWEEN ROS AND AUTOPHAGY: AUTOPHAGY
MODULATES MITOCHONDRIAL ROS
While the discussion has thus far focused on the impact of ROS
on the functional status of autophagy in response to various cel-
lular stressors, the autophagic pathway in turn modulates the
cellular levels of ROS. Autophagy is essential for the turnover
of normal mitochondria, as well as the removal of damaged
mitochondria, which are primary sources of intracellular ROS.
This speciﬁc form of autophagy is called mitophagy (Lemas-
ters, 2005; Youle and Narendra, 2011). Autophagy-deﬁcient cells
have signiﬁcantly higher ROS levels compared to their wild-type
counterparts (Mathew et al., 2009; Kongara et al., 2010). The
ROS scavenger NAC improves autophagy-deﬁcient cell survival
under metabolic stress in association with attenuation of p62
accumulation, indicating that excessive ROS results in p62 up-
regulation and impairment of cell survival (Mathew et al., 2009;
Kongara et al., 2010). Mammary tumors from FIP200f/f ;MMTV-
Cre;MMTV-PyMT mice are characterized by the presence of
abnormal mitochondria, as well as accumulation of both healthy
and dysfunctional mitochondria compared to the wild-type con-
trols (Wei et al., 2011), and conditional deletion of FIP200 in
hematopoietic stem cells and neural cells results in mitochon-
dria accumulation and increased ROS levels (Liang et al., 2010;
Liu et al., 2010). Morphologically abnormal mitochondria are
also observed in Atg7−/− livers (Komatsu et al., 2005; Inami
et al., 2011) and pancreatic β cells (Ebato et al., 2008; Jung
et al., 2008), Atg5−/− cardiac tissue (Nakai et al., 2007), and
Paneth cells with a hypomorphic allele of Atg16L1 (Cadwell
et al., 2008). Furthermore, increased ROS levels are associ-
ated with increased mitochondrial content in Atg5−/− MEFs
(Tal et al., 2009) and Atg7−/− T cells (Pua et al., 2009). Taken
together, all these studies indicate that mitophagy plays an essen-
tial role in recycling of functional and removal of damaged
mitochondria and clearly demonstrate that defective autophagy-
associated blocks in mitophagy lead to increased intracellular
levels of ROS, which in turn may be etiologically linked to
tumorigenesis.
Mitophagy has been extensively examined in normal devel-
opment, such as erythrocyte maturation, which involves devel-
opmental elimination of mitochondria from red blood cells,
as well as in the context of mitochondrial depolarization
induced by chemicals, such as CCCP (carbonyl cyanide m-
chlorophenylhydrazone). Mitochondrial elimination during ery-
throcyte maturation depends upon the outer mitochondrial
membrane protein NIP3-like protein X (Nix, also known as
BNIP3L), since Nix−/− reticulocytes retain their mitochondria
(Schweers et al., 2007; Sandoval et al., 2008). Similarly, ULK1−/−
and Atg7−/− reticulocytes exhibit delayed mitochondrial clear-
ance (Kundu et al., 2008; Zhang et al., 2009). Atg7−/− reticulo-
cytes also accumulate damaged mitochondria, accompanied by
increased ROS (Mortensen et al., 2010). Although Nix has been
shown to directly interact with LC3 via its WXXL motif (Novak
et al., 2010), its precise role in mitochondrial clearance remains
unclear.
While Nix is involved in removal of functional mitochondria
during normal red blood cell development, the serine/threonine
kinase PTEN-induced kinase1 (PINK1) and the E3 ubiquitin
ligase Parkin are essential for the elimination of damaged or
dysfunctional mitochondria. PINK1 is constitutively synthesized
and proteolytically degraded in normal mitochondria. Loss of
membrane potential and depolarization of damaged mitochon-
dria results in stabilization and accumulation of PINK1, which in
turn recruits cytoplasmic Parkin to abnormal mitochondria and
triggers mitophagy (Matsuda et al., 2010; Narendra et al., 2008,
2010a; Vives-Bauza et al., 2010). Parkin ubiquitinates mitochon-
drial proteins involved inmitochondrial fusion, such asmitofuscin
1 and 2 (MFN1 and 2), and results in their degradation (Gegg
et al., 2010; Poole et al., 2010; Rakovic et al., 2011). The precise
function of this degradation remains unknown, as are the details
of how Parkin stimulates mitophagy. p62/SQSTM1 is recruited
to damaged mitochondria by Parkin, but there are conﬂicting
reports regarding its requirement for mitophagy. Reduced mito-
chondrial clearance is observed in HeLa cells with a transient p62
knockdown upon treatment with the mitochondrial uncoupler
CCCP (Geisler et al., 2010). On the other hand, p62−/− MEFs
do not have a defect in mitochondrial clearance upon CCCP
treatment, despite the ﬁnding that p62 causes perinuclear, and
thus autophagosome-like, mitochondrial clustering (Okatsu et al.,
2010; Narendra et al., 2010b).
FUNCTIONAL INTERACTIONS BETWEEN AUTOPHAGY AND
ROS INTUMORIGENESIS
DNA DAMAGE AND GENOMIC INSTABILITY
As mentioned above, Becn1+/− iMMECs (Kongara et al., 2010)
and iBMK cells (Mathew et al., 2009) exhibit elevated intra-
cellular ROS levels compared to their wild-type counterparts
and, although not directly demonstrated, oxidative stress due
to excess ROS is likely contributing to the DNA damage and
genomic instability observed in autophagy-defective iMMECs and
iBMK cells in vitro and in their resultant allograft tumors in
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nude mice in vivo (Karantza-Wadsworth et al., 2007; Mathew
et al., 2007; Mathew et al., 2009), thus providing a plausible link
between autophagy defects, ROS accumulation, and enhanced
tumorigenic potential, especially in the background of impaired
apoptosis and cell cycle check-point defects (Karantza-Wadsworth
et al., 2007).
ROLE OF p62
Loss of Atg5 and Atg7 in mouse livers results in accumula-
tion of abnormal mitochondria, formation of inclusion bodies,
liver injury, and development of benign hepatocellular adeno-
mas (Komatsu et al., 2007; Inami et al., 2011; Takamura et al.,
2011). p62 is a component of these inclusion bodies, which
are cytoplasmic aggregates of ubiquitinated proteins commonly
associated with pathological conditions, such as Alzheimer’s
(Kuusisto et al., 2002), Huntington’s (Nagaoka et al., 2004), and
Parkinson’s (Kuusisto et al., 2001) diseases, as well as alco-
holic and non-alcoholic steatohepatitis (Zatloukal et al., 2002)
and hepatocellular carcinoma (Zatloukal et al., 2002). Combined
loss of p62 and autophagy in Atg7−/−; p62−/− livers abro-
gates inclusion body formation, alleviates hepatic injury and
retards tumor progression compared to Atg7−/− deﬁciency alone
(Komatsu et al., 2007; Takamura et al., 2011). On the contrary,
p62 overexpression increases ROS and accelerates tumorige-
nesis in an autophagy-defective background, but not in an
autophagy-competent one (Mathew et al., 2009), suggesting that
the tumor-forming abilities of autophagy-deﬁcient cells may be
dependent on persistent and abnormal p62 accumulation, which
is the result of combined p62 induction in response to defective
autophagy-associated oxidative stress and impaired p62 elimi-
nation, again due to deﬁcient autophagy. As explained below,
p62 in turn activates prosurvival antioxidant cell responses,
including the nuclear factor erythroid 2-related factor 2 (Nrf2)
pathway, but in aggregate form also leads to further ROS pro-
duction, thereby maintaining a potentially tumorigenic vicious
cycle.
p62/SQSTM1 activates the Nrf2 pathway in a non-canonical
manner and likely modulates ROS levels as a consequence. Nrf2
is a transcription factor, which under normal growth conditions
is constitutively targeted for degradation by the Kelch-like ECH-
associated protein 1 (Keap1) complex (Taguchi et al., 2011). Upon
induction of oxidative stress, Keap1 undergoes conformational
changes leading to the release, stabilization, and translocation of
Nrf2 into the nucleus, where it activates the transcription of genes
under control of the antioxidant responsive element (ARE), which
in turn function to restore physiological ROS levels (Taguchi et al.,
2011). p62 competes with Nrf2 for binding sites on Keap1, result-
ing inNrf2 stabilization and enabling its nuclear translocation and
activation of target genes, including p62, thus resulting in a posi-
tive feedback loop (Jain et al., 2010; Komatsu et al., 2010; Lau et al.,
2010). Indeed, under autophagy-deﬁcient conditions, Keap1 is a
component of inclusion bodies together with p62 and is, similar
to p62, also degraded via autophagy (Jain et al., 2010; Komatsu
et al., 2010). As expected, liver-speciﬁc Atg7 loss activates the Nrf2
pathway, while simultaneous p62 loss abrogates this activation
(Komatsu et al., 2007; Inami et al., 2011). Importantly, similar to
concurrent p62 and Atg7 loss, combined Nrf2 and Atg7 deﬁciency
alleviates the cellular injury observed in Atg7−/− livers, whereas
combined loss of Keap1 and Atg7 exacerbates hepatocyte damage
(Komatsu et al., 2010). Taken together, these results indicate that
liver injury due to autophagy defects is driven by p62 accumulation
and its resultant activation of the Nrf2 pathway. In support of this
hypothesis, p62 deletion in the human hepatocellular carcinoma
cell line Jhh-5 diminishes its colony-forming ability in soft agar
in conjunction with failure to activate Nrf2 (Inami et al., 2011).
Whether Nrf2 activity is required for the formation of tumors in
the context of autophagy deﬁciency and p62 accumulation in vivo
remains to be investigated.
In addition to up-regulating theNrf2 antioxidant response, p62
modulates ROS levels by also activating the nuclear factor kappa
B (NF-κB), which is known to be induced by and also regulate
ROS (Duran et al., 2008; Morgan and Liu, 2011). The absence
of p62 delays tumor formation and reduces tumor burden in a
tetracycline-inducible K-Ras model of lung tumorigenesis, and
this effect is attributed to loss of NF-κB activity in the p62−/−
background (Duran et al., 2008). Similarly,H-RasV12-transformed
p62−/− MEFs, when compared to their wild-type counterparts,
exhibit higher levels of apoptosis in association with increased
JNK activity, which in turn is caused by elevatedROS levels (Duran
et al., 2008). Treatment of H-RasV12-transformed p62−/− MEFs
with the antioxidant butylated hydroxyanisole (BHA) restores
cell viability, indicating that excessive ROS is responsible for the
increase in cell death (Duran et al., 2008). Intriguingly, in an
autophagy-deﬁcient background, p62 aggregation and oligomer-
ization impair its ability to activate the NF-κB pathway, thereby
mimicking a functional loss of p62 with respect to this particu-
lar pathway, and may partly explain the increased ROS associated
with autophagy deﬁciency (Mathew et al., 2009). Thus, p62 accu-
mulation accompanying impaired autophagy fails to activate the
NF-κB pathway, leading to increased ROS production, while it
simultaneously activates the antioxidant Nrf2 pathway via Keap1
sequestration. The balance between increased ROS production
and ROS tempering via the Nrf2 pathway may be an impor-
tant player in tumor progression in the context of autophagy
deﬁciency.
INFLAMMASOME ACTIVATION
Inﬂammasomes are multi-protein complexes responsible for the
processing of caspase-1 and the subsequent maturation and secre-
tion of the proinﬂammatory cytokines interleukin IL-1β and
IL-18 (Martinon et al., 2009). The nucleotide-binding oligomer-
ization domain (NOD)-like receptor (NLR) family, pyrin domain-
containing 3 (NLRP3) inﬂammasome consists of the NLR family
member NLRP3, the adaptor apoptosis-associated speck-like
(ASC) protein and pro-caspase-1, and is activated in response
to diverse stimuli, such as bacteria, viruses, silica, asbestos, uric
acid crystals, ATP, lysosomal damage, and impaired phagocyto-
sis (Martinon et al., 2009; Gross et al., 2011). Proteolytic activity
of the NLRP3 inﬂammasome requires two steps: (1) priming,
which is characterized by the transcriptional up-regulation of
NLRP3 and pro-IL-1β, and (2) activation, which involves the
oligomerization of NLRP3 in response to various stimuli (Chen
and Nunez, 2011; Gross et al., 2011). Interestingly, ROS are
critical mediators of inﬂammasome activity, most likely at the
Frontiers in Oncology | Molecular and Cellular Oncology November 2012 | Volume 2 | Article 171 | 6
“fonc-02-00171” — 2012/11/19 — 21:33 — page 7 — #7
Kongara and Karantza Autophagy and ROS in cancer
priming step (Bauernfeind et al., 2011), since antioxidants atten-
uate IL-1β maturation in response to uric acid crystals (Petrilli
et al., 2007; Dostert et al., 2008), asbestos (Dostert et al., 2008),
and ATP (Cruz et al., 2007; Dostert et al., 2008). In agreement
with the above ﬁndings, defective autophagy-induced mitochon-
drial ROS also lead to inﬂammasome activation (Nakahira et al.,
2011; Zhou et al., 2011), and macrophages isolated from Atg7−/−,
Atg16L1−/−, LC3B−/−, and Becn1+/− mice secrete elevated levels
of IL-1β and IL-18 upon stimulation (Saitoh et al., 2008; Nakahira
et al., 2011), thus intimately linking autophagy impairment
to inﬂammasome activation and its resultant inﬂammatory
response.
FIGURE 1 | Reactive oxygen species-mediated autophagy regulation.
The ULK1/2–FIP200–mAtg13 and Beclin1–Vps34–p150 protein complexes
together with the two ubiquitin-like proteins Atg12 and LC3 (or Atg8) and
their conjugating proteins, including Atg7 (E1-like enzyme), Atg10 (E2-like
enzyme), and Atg3 (E2-like enzyme), are the primary regulators of
autophagosome formation and, thus, autophagy induction. Atg4 cleaves
Pro-LC3 at its C-terminal-end, Atg7 and Atg3 add phosphatidyl ethanolamine
(PE), and LC3-PE is then incorporated into the autophagosome membrane;
Atg4 can also cleave LC3-PE to release free LC3 and negatively impact
autophagy. The PI3K–Akt–mTORC1 pathway suppresses autophagy by
inhibiting the ULK1/2–FIP200–mAtg13 complex. PI3K is activated in
response to hormones and growth factors and suppressesTSC1/2 activity,
thus resulting in Akt and mTORC1 activation; the phosphatase PTEN
antagonizes PI3K, while the peroxiredoxins Prdx1 and 2 maintain PTEN
function by preventing its oxidation. mTORC1 is also negatively regulated
by HIF-1α via BNIP3 induction and by ATM via LKB1 and AMPK. The
Beclin1–Vps34–p150 complex is positively regulated by Bif-1, UVRAG,
AMBRA, and HMGB1, and negatively regulated by Bcl-2 and RUBICON.
ROS stimulate autophagy by activating HIF-1α, AMPK, ATM, HMGB1,
JNK1, ERK1/2 and inhibiting the PE-cleaving activity of Atg4, without
affecting its ability to process the C-terminal end of LC3. ROS inhibit
PTEN and are hypothesized to negatively affect TSC1/2 activity,
potentially inhibiting autophagy. Upon its induction, autophagy results in
ROS suppression.
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The connection between inﬂammasome-associated cytokine
production and tumorigenesis is complex, as IL-1β and IL-18
have both pro- and anti-tumorigenic effects. In support of a
tumor-promoting role, loss of IL-1β slows the progression of
tumors in a model of chemical-induced carcinogenesis (Krelin
et al., 2007), implantation of B16 melanoma cells in IL-1β-null
mice prevents the formation of tumors as well as lung metas-
tases (Vidal-Vanaclocha et al., 2000; Voronov et al., 2003), Lewis
lung carcinoma cells overexpressing IL-1β exhibit accelerated
rate of tumor formation accompanied by increased vascula-
ture (Saijo et al., 2002), and IL-1β-overexpressing A459 cells
form lung metastasis more efﬁciently than control cells, in a
process inhibited by an antibody to IL-1β (Yano et al., 2003).
Furthermore, implantation of mammary carcinoma 4T1 cells in
IL-1 receptor-null (IL-1R−/−) mice slows tumor progression in
association with immune suppression (Bunt et al., 2007), and
ﬁbroblast growth factor receptor-1 (FGFR-1)-mediated mam-
mary tumorigenesis is dependent on the induction of IL-1β
and inhibited by administration of anti-IL-1β antibody (Reed
et al., 2009). Taken together, these studies implicate IL-1β in
promotion of tumor cell proliferation, migration, angiogene-
sis, invasion, and inhibition of immune surveillance. Studies
conducted on IL-18 indicate that IL-18 increases apoptosis and
decreases metastasis in experimental models of bone metastasis
(Ohtsuki et al., 1997; Nakata et al., 1999; Iwasaki et al., 2002);
however, IL-18 has also been reported to increase angiogene-
sis (Park et al., 2001) and suppress immune surveillance (Terme
et al., 2011).
While earlier studies indicated that IL-1β and IL-18, together
with other components of the inﬂammasome, exacerbate colitis
and promote colitis-associated cancer (Siegmund et al., 2001a,b;
Sivakumar et al., 2002; Ishikura et al., 2003; Loher et al., 2004;
Bauer et al., 2007), more recent evidence suggests that these
molecules play a protective role by impeding colitis and pro-
gression to cancer (Takagi et al., 2003; Allen et al., 2010; Dupaul-
Chicoine et al., 2010; Salcedo et al., 2010; Zaki et al., 2010a,b). The
reason for this discrepancy is unclear, although it can be partly
attributed to differences in gut-residing microﬂora and in exper-
imental design (Zaki et al., 2011). Furthermore, components of
the inﬂammasome, and in particular IL-1β, are required for the
efﬁcient recruitment of the immune system to attack tumor cells
upon chemotherapeutic treatment (Ghiringhelli et al., 2009). In
conclusion, modulation of tumor growth and survival by IL-1β
and IL-18 is complex and likely context-dependent. Similarly,
FIGURE 2 | Interplay between ROS and autophagy in tumorigenesis.
Autophagy is induced by ROS and functions to mitigate oxidative stress.
Defective autophagy leads to ROS accumulation and mitochondrial damage;
in turn, malfunctioning mitochondria become additional sources of ROS,
thereby creating a vicious cycle.While moderately high ROS levels are
mutagenic and likely mediate tumor initiation in association with autophagy
defects, very high ROS levels may result in apoptosis, and, thus, inhibit both
tumor initiation and progression.
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how inﬂammasome activation due to autophagy defects impacts
tumorigenesis remains unclear and has understandably become a
vigorously investigated subject.
SUMMARY
The functional interactions between autophagy and ROS are
elaborate (Figure 1) and their role in tumorigenesis is complex
(Figure 2), and likely tissue- and context-dependent. Excess ROS
up-regulate autophagy by multiple and at times counteracting
mechanisms, and in turn this catabolic cellular process restores
physiological ROS levels. Defective autophagy promotes the accu-
mulation of damagedmitochondria and results in oxidative stress,
whichmay be partly responsible for the tumor-forming abilities of
autophagy-deﬁcient cells by functioning as a genotoxic and muta-
genic agent and by triggering secondary, non-cell autonomous
effects, such as inﬂammation.
The ﬁnding that Atg5−/− or Atg7−/− mouse livers give rise
to benign adenomas, but not malignant hepatocellular carcino-
mas, is likely indicative of the opposing roles that autophagy
may plays at different stages of tumorigenesis. Chronic impair-
ment of autophagy may be detrimental to cellular health due
to accumulation of aggregated proteins and damaged organelles,
such as aging mitochondria, thus leading to steadily rising,
protumorigenic levels of ROS over time. Since autophagy is
one of the primary mechanisms by which cells moderate ROS,
autophagy impairment can create a vicious cycle, where inabil-
ity to temper slightly elevated ROS levels leads to further ROS
production, which, if it exceeds a critical threshold, may trig-
ger cell death, and thus, impede tumor progression. Accumu-
lating evidence indicates that tumors driven by metabolically
demanding oncogenes, such as mutant Ras and PyMT, also
depend on autophagy. Indeed, oncogenic Ras-driven tumors
rely on mitochondrial oxidative phosphorylation to meet their
metabolic needs, and autophagy is critical for the supply of
essential metabolic intermediates and the maintenance of mito-
chondrial health. In parallel to increased metabolic demands,
potent oncogene activation is also associated with excess ROS
production and, thus, autophagy may not only support can-
cer metabolism, but also function as a toxic ROS scavenger to
again promote tumor cell survival and enable cancer progres-
sion.
In conclusion, the functional status of autophagy is intri-
cately connected to intracellular ROS levels in complex ways,
and these elaborate interactions likely impact tumorigenesis in
context-speciﬁc manners that are worthy of further investiga-
tion and may provide novel insights into how to best phar-
macologically modulate autophagy for cancer prevention and
treatment.
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